Viatris (VTRS)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$16.88-0.35%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · VTRS
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -28.9% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 1.5% |
Growth built into the price is above our model estimate.
The price assumes 30.4 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 23 industry peers · Company calendar date is not available
VTRS — credit agreement
Dated 2026-07-01
Entry into a Material Definitive Agreement. On July 1, 2026 (the “Closing Date”), Viatris Inc. (“Viatris”) entered into an amended and restated term loan credit agreement (the “Amended and Restated Term Loan Credit Agreement”), among Viatris, the guarantors from time to time party thereto, the lenders from time to time party thereto and Mizuho Bank, Ltd., as administrative agent. The Amended and Restated Term Loan Credit Agreement provides for a ¥40,000,000,000 principal amount senior unsecur…
Why it matters: A smooth transition is key for keeping investor trust and stable operations.
Watch forThey announced a new CFO with a clear plan for managing finances.
Also watch forDelays or problems in finding a new CFO could hurt financial operations.
Why it matters: Reaffirming guidance shows Viatris' commitment to its financial targets. It signals confidence in growth.
Supportive ifViatris confirms 2026 revenue guidance between $14,450M and $14,950M in the next earnings call.
Worry ifViatris revises down its 2026 revenue guidance below $14,450M in the next earnings call.
Why it matters: Confirming plans shows trust in future results. Changes could mean bigger problems.
Watch forManagement confirms the 2026 financial plans with no changes.
Also watch forManagement cuts the financial plans for 2026.
Why it matters: Strong cash flow is key. It helps fund growth and keeps finances healthy.
Supportive ifViatris reports cash from operations over $1.85 billion in Q2 2026.
Worry ifCash from operations drops below $1.7 billion in Q2 2026.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$111 on $10,000 · ±1.1% | How much price usually moves either way. |
| Bad day | $248 loss on $10,000 · 2.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $1,897 loss on $10,000 · 19.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Earnings results will show how well the company is doing in money and operations.
Watch forEarnings report shows revenue growth above 5% year over year.
Also watch forEarnings report shows revenue growth below 0% year over year.
Why it matters: News on capital allocation, like share buybacks, can affect investor trust and stock value.
Watch forViatris announces a big share buyback plan during the Q2 earnings call.
Also watch forViatris provides no updates or cancels the share buyback program during the Q2 earnings call.
Why it matters: A smooth CFO change is important. It helps keep investor trust and financial stability.
Watch forViatris announces a new CFO appointment by the next earnings call.
Also watch forNo new CFO is appointed by the next earnings call, causing uncertainty.
Why it matters: This review is crucial for cutting costs and improving efficiency. Delays could hurt financial health.
Worry ifManagement says they made good progress on the review. The score is above 50%.
Less concerning ifNo progress reported, keeping the score at 0% or lower.
Why it matters: The CFO's departure could change financial strategy. It may also affect investor confidence.
Worry ifA new CFO is appointed quickly. Investors respond positively to this news.
Less concerning ifDelay in appointing a new CFO or negative market reaction to the transition.
Why it matters: A higher leverage ratio may show financial stress. This can affect capital plans.
Worry ifGross leverage ratio exceeds 3.0x in future reporting.
Less concerning ifGross leverage ratio remains at or below 2.9x.
Why it matters: A new CFO might change financial plans or guidance. This could affect what investors expect.
Watch forThe new CFO gives a positive financial outlook or confirms the current guidance.
Also watch forThe new CFO issues a cautious or negative financial outlook.
Why it matters: This acquisition is important for Viatris' eye care business. It could help future growth.
Supportive ifViatris finishes buying Oyster Point Pharma by the end of Q2 2023.
Worry ifThe acquisition fails to close or faces significant delays beyond Q2 2023.
Why it matters: Successful product launches can drive revenue growth. They are critical for Viatris' future.
Supportive ifViatris reports new product revenues of at least $450M to $550M in 2026.
Worry ifNew product revenues fall below $450M in 2026.
Why it matters: This shows revenue growth is slowing. This raises worries about how well the company is doing.
Worry ifQ3 total revenues growth falls below 3.5% compared to Q3 2025.
Less concerning ifQ3 total revenues growth meets or exceeds 3.5% compared to Q3 2025.
Why it matters: The timing of this launch could impact revenue growth from new products significantly.
Supportive ifGwyn Lo will be available for sale by the end of 2026.
Worry ifGwyn Lo launch is delayed beyond 2026.
Why it matters: Hitting this goal shows the company is launching products well. It also shows progress in their plans.
Supportive ifNew product revenues for 2026 reach at least $450 million.
Worry ifNew product revenues fall below $450 million for 2026.
Why it matters: More money returned to investors shows strong cash flow. It also shows a focus on shareholder value.
Supportive ifIn 2026, the company will give back more than $550 million to shareholders.
Worry ifIn 2026, the company will give back less than $550 million to shareholders.